Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 3/20 | 0.71 |
| ▸ | PRMT5 | O14744 | 12/20 | 0.65 |
| ▸ | WDR77 | Q9BQA1 | 9/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25910580 | 1.00 | CARM1 (0.71) | CARM1PRMT5WDR77MEN1KMT2A | |
| SCHEMBL20042490 | 1.00 | CARM1 (0.71) | CARM1PRMT5WDR77MEN1KMT2A | |
| SCHEMBL30019323 | 0.90 | CARM1 (0.74) | CARM1PRMT5WDR77HTTLMNA | |
| SCHEMBL17813632 | 0.85 | CARM1 (0.68) | CARM1PRMT5WDR77HTTLMNA | |
| SCHEMBL30285329 | 0.84 | CARM1 (0.67) | CARM1PRMT5WDR77HTTLMNA | |
| SCHEMBL29373628 | 0.84 | CARM1 (0.67) | CARM1PRMT5WDR77HTTLMNA | |
| SCHEMBL29374314 | 0.84 | CARM1 (0.67) | CARM1PRMT5WDR77HTTLMNA | |
| SCHEMBL28823752 | 0.84 | CARM1 (0.72) | CARM1PRMT5WDR77HTTLMNA | |
| SCHEMBL15823999 | 0.84 | CARM1 (0.67) | CARM1PRMT5WDR77HTTLMNA | |
| SCHEMBL9476995 | 0.84 | CARM1 (0.67) | CARM1PRMT5WDR77HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3498701-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-9604930-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-03-28 | — | — | US | disclosed |
| WO-2016089883-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2016-06-09 | — | — | WO | disclosed |
| US-20150344434-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20090093493-A1 | 1-PHENYLALCOXY-2-BETA-PHENYLETHYL DERIVATIVES AS P-GLYCOPROTEIN (P-GP) INHIBITORS USEFUL IN DRUG RESISTANCE EVENTS | UNIVERSITA DI PISA, 40% (IT) | 2009-04-09 | — | — | US | disclosed |
| US-20090093493-A1 | 1-PHENYLALCOXY-2-BETA-PHENYLETHYL DERIVATIVES AS P-GLYCOPROTEIN (P-GP) INHIBITORS USEFUL IN DRUG RESISTANCE EVENTS | UNIVERSITA DI PISA, 40% (IT) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093493-A1 | 1-PHENYLALCOXY-2-BETA-PHENYLETHYL DERIVATIVES AS P-GLYCOPROTEIN (P-GP) INHIBITORS USEFUL IN DRUG RESISTANCE EVENTS | ABCB1, ABCC1, ABCC2 | CARM1 4515/4885PRMT5 4117/4885WDR77 4165/4885 |
| US-20150344434-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | CARM1 8/4885PRMT5 1/4885WDR77 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.